OXFORD

COMPUTATIONAL BIOMEDICINE

MODELLING THE HUMAN BODY

PETER COVENEY, VANESSA DÍAZ-ZUCCARINI, PETER HUNTER & MARCO VICECONTI

COMPUTATIONAL BIOMEDICINE

MODELLING THE HUMAN BODY

Edited by

Peter V. Coveney, University College London

Vanessa Díaz-Zuccarini, University College London

Peter Hunter, University of Auckland and University of Oxford

常州大字山北州arco Viceconti, University of Sheffield 滅 书 章





Great Clarendon Street, Oxford OX2 6DP, United Kingdom

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries

© Oxford University Press 2014

The moral rights of the authors have been asserted

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above

You must not circulate this work in any other form and you must impose this same condition on any acquirer

Published in the United States of America by Oxford University Press 198 Madison Avenue, New York, NY 10016, United States of America

British Library Cataloguing in Publication Data
Data available

Library of Congress Control Number: 2013956438

ISBN 978-0-19-965818-3

Printed in Great Britain by Bell & Bain Ltd, Glasgow

Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work.

Computational Biomedicine

PRFFACE

At the present time, medicine is on the verge of a radical transformation driven by the inexorably increasing power of information technology. We live in what is sometimes called the digital era, wherein information is widely accessible in electronic form, made available over the Internet by the worldwide web. Medical information is no different, and today there is a relentless push to digitize healthcare data, for example in the form of electronic health records, making it more facile for patients, doctors, and other healthcare workers to track the records of individual patients, to improve treatments, and to monitor outcomes of clinical care.

Of course, medicine and human health are intensely personal matters, as well as being subject to scientific understanding, and so accessing such data is surrounded by necessary considerations of privacy and confidentiality. The security of personal healthcare data is subject to rules and regulations in information governance which frequently threaten to undermine the entire programme of digital medicine, when the balance between access to such records is countered by arguments about the need to maintain patient privacy. At all times it is essential to remember that access to such data has the potential to enable medical cures and improve people's lives, while overly zealous attention to protection of personal privacy denies this.

As and when access to human healthcare data is permitted, modern science can progress rapidly. The immediate wins in basic and clinical medicine centre on the analysis of large collections of such data, using a variety of methods collectively referred to today as machine learning. These methods are inherently statistical in nature, providing inferences about medical conditions based on correlations between 'input' and 'output' variables. Their computational cost is relatively low and many medical discoveries of this nature are possible by the mining of vast

quantities of data. One of the most promising of such approaches is stratification, the clustering of subsets of the population into groups which are found to be susceptible to a particular disease and, more importantly, a specific form of medical treatment. With increasing quantities of data, particularly whole human genomes being acquired with astonishing speed from so-called next-generation sequencing technology, there is an expectation that we will discover well-defined clustering of human populations, along with the aspiration that we shall be able to target these groups with different treatments (thus, for example, drugs, regimens, and so on can be tailormade to stratified groups). At this point, medicine for the masses (a kind of average way of treating everyone) becomes more about medicine for welldefined groups of patients.

Thus digital technology points to a new era of stratified medicine, in which specific electronic information on a patient allows a doctor to perform a treatment better tailored to the individual concerned. We are all different, however, and such statistical approaches, being based on data acquired on populations of many different patients, inevitably smear out individual differences. In the case of rare diseases, for example, there may not even be a sufficient number of other similar conditions to make reliable inferences. As we discover more about the intricacies of other diseases—cancer is one case in point—it is becoming clear that the mechanisms behind a disease can vary significantly from one patient to another.

To go beyond the power of inference-based methods, and to develop a truly personalized form of medicine, a different approach is required, one in which a deeper understanding of the *mechanisms* of disease are taken into account. These mechanisms may vary to a greater or lesser extent between individuals, and understanding these differences opens

the door to more scientific ways of treating the disease and curing it in a convincing manner. Full control of disease cases will emerge when we understand these mechanisms in a quantitative manner, and are able to reliably predict individual outcomes before applying treatments. This depends on our ability to mathematically represent and thus model the human body and its pathologies. The human body is a complex system, and its mathematical description necessitates the running of models on computers, a medical form of computer simulation. This too is heavily dependent on information technology, including an ability to access powerful computers as well as large-scale data, the aim being to produce 'high-fidelity' descriptions of medical conditions and the effects of proposed treatments, before these are performed. It is this new approach to medical science that forms the basis of this textbook.

We look at the many levels of biological organization in the human body, from the molecular through cellular and tissue to organ systems, and how one can successfully begin to model these using principles taken from the physical and engineering sciences. These approaches always combine some patient-specific data—it might be from a genomic analysis, one or more imaging modalities, or combinations of these—with a mathematically based mechanistic model. In some cases, such models are already gaining a reasonable degree of personal human fidelity and are being used in research contexts to address clinical conditions.

Because the various levels of physiological organization are not independent but in reality influence one another to varying degrees, the modelling challenge we face is compounded by the need to consider how processes occurring on these levels, often on very different space and time scales, interact. This is the heart of systems biology, although it might better be referred to as 'systems medicine' in the present context. The use of 'systems' here implies that we are addressing a multi-scale problem upon which the overall physiological or pathological behaviour depends. And so we look at how multi-scale modelling and simulation are performed today too.

Beyond that, there are the practical issues of how to perform many complex and demanding human body simulations, in a timely and reliable manner, through the use of computer automation, by exploiting computational workflows and distributed high-performance computing environments.

Underpinning all of these emerging capabilities is the management of healthcare data collection and provision with all the attendant privacy issues, which is linked closely to the legal frameworks that pertain within individual countries and for international collaboration. We describe the architecture of the informatics platforms necessary to manage access to patient data in a suitably anonymized format, while permitting the reverse linkage to patient identity in cases where this is needed, in conformance with legal and ethical requirements.

For the future deployment of such models and simulations in clinical decision making it is vital that they are fully verified and validated. This issue, central for building confidence in the medical community, is also in fact a key issue in all forms of computational science today, and receives attention in the final chapter of the book.

To whom is our textbook addressed? Plainly the scope of the domains covered is dauntingly broad and we cannot reasonably expect all readers to be able to comprehend everything in detail. We have primarily focused on providing a comprehensible account for advanced undergraduates and beginning postgraduate students who have a background in any of mathematics, physical sciences, engineering, and computer science. That is, we have tried to present the required biology and medicine to readers who are familiar with mathematics (including discrete and continuous dynamical systems, and ordinary and partial differential equations), numerical analysis, and programming, but who need more explanation about the human phenomena that they will need to model.

We hope that this textbook will provide a firm foundation for future generations to build on the initial progress now being made in predictive mechanistic modelling of the human body using computers. These are the very first steps along the path to virtual humans which we hope will one day assist in enhancing health and wellbeing for all the inhabitants of this planet.

Finally, we wish to thank the many friends and colleagues who have contributed chapters to this book (they are all listed at the start of this book and at the end of the chapters they have composed), along with numerous others who provided critical and constructive feedback to us at all stages along the way to the published book. We are especially grateful to Dr Clare Sansom who has acted as Assistant Editor to us in the labour of taking all of the original content and transforming it into a homogeneous textbook. In all matters pertaining to the production of the book we are indebted to Jonathan Crowe, our commissioning editor at Oxford University Press, who

has taken a very close interest in this work from inception to completion.

Peter V. Coveney Vanessa Díaz-Zuccarini Peter Hunter Marco Viceconti 25 October 2013

ABOUT THE EDITORS

Peter Coveney holds a Chair in Physical Chemistry, is Director of the Centre for Computational Science, and is an Honorary Professor in Computer Science at University College London. He is also Professor Adjunct within the Medical School at Yale University. Coveney is active in a broad area of interdisciplinary theoretical research including condensed matter physics and chemistry, materials science, life and medical sciences. He has published over 350 scientific papers and texts including two best-selling popular science books, *The Arrow of Time* and *Frontiers of Complexity*.

Vanessa Díaz-Zuccarini is a lecturer in Bioengineering at University College London. Working at the interface of systems biology and engineering, she is the founder of the Multiscale Cardiovascular Engineering Group in UCL, which she now leads. Her research aims to apply multi-physics and multi-scale computational techniques to tackle challenges in cardiovascular science from a patient-specific point of view. She focuses on the modelling and simulation of cardiovascular physiology and pathology by using a combination of systems biology and information and communication technologies for health and biomechanics. She has a strong interest in bringing research results to the clinic and has developed close links with UCL-affiliated hospitals, particularly the vascular unit at University College Hospital and the Institute of Child Health.

Peter Hunter FRS is Professor of Engineering Science and Director of the Bioengineering Institute at the University of Auckland, New Zealand, and co-Director of Computational Physiology at the University of Oxford, UK. As a recent Chair of the Physiome Committee of the International Union of Physiological Sciences he has helped to lead the international Physiome Project, which is using computational methods to understand the integrated physiological function of the body in terms of the structure and function of tissues, cells, and proteins. He has been involved with developing many of the standards necessary to facilitate reproducible multi-scale modelling.

Marco Viceconti holds the chair of Biomechanics within the Department of Mechanical Engineering of the University of Sheffield and serves as Scientific Director of the Insigneo Institute for *in silico* medicine there. His main research interests are in the development and validation of medical technology for neuromusculoskeletal diseases. Viceconti is a central figure in the emerging Virtual Physiological Human (VPH) community: co-ordinator of the VPH research roadmap and of the VHPOP osteoporosis project, and 'VPH ambassador' for the VPH Network of Excellence. He is the current chair of the Board of Directors of the VPH Institute, an international non-profit organization.

CONTRIBUTING AUTHORS

Assistant Editor: Clare Sansom, Birkbeck, University of London, London, UK

Chapter 1

Peter V. Coveney, University College London, UK Denis Noble, University of Oxford, Oxford, UK

Chapter 2

- Imad Abugessaisa, The Unit of Computational Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- David Gomez-Cabrero, The Unit of Computational Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- Jesper Tegnér, The Unit of Computational Medicine, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Chapter 3

- Jon Olav Vik, Centre for Integrative Genetics, Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, Ås, Norway
- Arne B. Gjuvsland, Centre for Integrative Genetics, Department of Animal and Aquacultural Sciences, Norwegian University of Life Sciences, Ås, Norway
- Bernard De Bono, Auckland Bioengineering Institute (ABI), University of Auckland, New Zealand; Centre for Health Informatics & Multiprofessional Education (CHIME), University College London, 3rd Floor, Wolfson House, Stephenson Way, London NW1 3HE, UK
- Stig W. Omholt, Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway

Chapter 4

- Alejandro Frangi, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain and Department of Mechanical Engineering, University of Sheffield, Sheffield, UK
- Denis Friboulet, Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, France
- Nicholas Ayache, Inria Asclepios Team, Sophia Antipolis, France
- Hervé Delingette, Inria Asclepios Team, Sophia Antipolis, France
- Tristan Glatard, Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, France
- Corné Hoogendoorn, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- Ludovic Humbert, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- Karim Lekadir, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- Ignacio Larrabide, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- Yves Martelli, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain

- Françoise Peyrin, Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, France
- Xavier Planes, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- Maxime Sermesant, Inria Asclepios Team, Sophia Antipolis, France
- Maria-Cruz Villa-Uriol, Department of Mechanical Engineering, University of Sheffield, Sheffield, UK
- Tristan Whitmarsh, Center for Computational Imaging & Simulation Technologies in Biomedicine, Information & Communication Technologies Department, Universitat Pompeu Fabra, Barcelona, Spain
- David Atkinson, UCL Centre for Medical Imaging, 250 Euston Road, London NW1 2PG, UK

Chapter 5

- James B. Bassingthwaighte, Department of Bioengineeering, University of Washington, Seattle, USA
- Colin Boyle, Department of Mechanical Engineering, University College London, London, UK
- Cesar Pichardo-Almarza, InScilico Ltd, London, UK
- Vanessa Díaz-Zuccarini, Department of Mechanical Engineering, University College London, London, UK

Chapter 6

S. Randall Thomas, IR4M UMR8081 CNRS, Orsay & Villejuif, France and Université Paris-Sud XI, Orsay, France

Rod Smallwood, University of Sheffield, Sheffield, UK Nic Smith, King's College, London, UK Cesar Pichardo-Almarza, InScilico Ltd, London, UK

Chapter 7

- Alfons Hoekstra, Computational Science, Faculty of Science, University of Amsterdam, The Netherlands
- Bastien Chopard, Computer Science, University of Geneva, Switzerland
- Pat Lawford, Medical Physics Group, Department of Cardiovascular Science, University of Sheffield, UK

Chapter 8

Daniel A. Silva Soto, University of Sheffield, Sheffield, UK Steven Wood, Sheffield Teaching Hospitals, Sheffield, UK Susheel Varma, University of Sheffield, Sheffield, UK Rodney Hose, University of Sheffield, Sheffield, UK

Chapter 9

- Stefan J. Zasada, Centre for Computational Science, University College London, London, UK
- Peter V. Coveney, Centre for Computational Science, University College London, London, UK

Chapter 10

- Ali Nasrat Haidar, Centre for Computational Science, University College London, 20 Gordon Street, London, WC1H 0AJ, UK
- Nikolaus Forgó, Institut für Rechtsinformatik/Institute for Legal Informatics, Leibniz Universität, Hannover, Germany
- Hartwig Gerhartinger, Institut für Rechtsinformatik/ Institute for Legal Informatics, Leibniz Universität, Hannover, Germany

Chapter 11

Marco Viceconti, University of Sheffield, Sheffield, UK Norbert Graf, Saarland University, Saarbrücken, Germany

Appendix

- Poul Nielsen, Auckland Bioengineering Institute (ABI), University of Auckland, New Zealand
- Bernard De Bono, Auckland Bioengineering Institute (ABI), University of Auckland, New Zealand; Centre for Health Informatics & Multiprofessional Education (CHIME), University College London, 3rd Floor, Wolfson House, Stephenson Way, London NW1 3HE, UK
- Peter Hunter, Auckland Bioengineering Institute (ABI), University of Auckland, New Zealand and University of Oxford, Oxford, UK

With additional thanks to Benjamin Bhattacharya-Ghosh for his assistance with the production of a number of the figures.



CONTENTS

Contributing Authors		3.4 Implementing cGP Models	44
		Box 3.3 Monte Carlo Methods Box 3.4 Models of Gene Regulation	46 48
1 Introduction	1	3.5 Some cGP Applications	49
1.1 Introduction	1	3.6 Linking cGP Models to Data	51
1.2 Systems Biology	2	3.7 Conclusions	56
1.3 Initiatives for Modelling Human Physiology	3	Recommended Reading	57
1.4 Book Synopsis	3	References	57
References	5	References	21
		4 Image-Based Modelling	59
2 Molecular Foundations of Computational		4 Illiage-based Modelling	39
Bioscience	6	4.1 Introduction	59
2.1 Introduction	6	4.2 Image-Based Modelling	66
2.2 DNA and its Data Formats	8	4.3 Simulating the Physics of Image Formation	75
2.3 RNA and its Data Formats	13	4.4 Statistical Atlases, Population Imaging, and	
		Modelling	78
2.4 Proteins and their Data Formats	18	4.5 Open-Source Tools for Image-Based	
2.5 Metabolism, Metabolites, and their Databases	21	Modelling	79
2.6 Integrating Different Data Types and	21	4.6 Conclusions	81
Sources	22	Recommended Reading	82
2.7 Management of Omics Data Types Box 2.1 Example of the Use of Multiple	24	References	82
Databases to Answer a Specific Research		5 Modelling Cell Function	84
Question	25		
2.8 Software Systems: Security and		5.1 Introduction	84
Interoperability	29	5.2 General Functions of Cells	87
2.9 Conclusions	30	5.3 Fundamentals of Reactions in Cells	88
Recommended Reading	32	Box 5.1 The Cell as a Complex System 89 5.4 Formalisms and Abstractions in Cell	
References	32	Modelling	92
		5.5 Modelling Approaches	94
3 From Genotype to Phenotype	33	Box 5.2 Compartmental Models of the	
3.1 Introduction	33	Cell Using ODEs	96
3.2 Quantitative Genetics: A Brief Introduction	35	5.6 Simulation Tools	101
3.3 Systems Genetics	37	5.7 Reproducible Cell Modelling	104
Box 3.1 A cGP Model of the Action	37	Box 5.3 Case Study: A Reproducible	
Potential of a Heart Muscle Cell	41	'Validated' Model of Hepatic Clearance Using ODEs	106
Box 3.2 Refining the Genotype-to-		5.8 Conclusions	100
Parameter Map: From Nucleotide Mutation			109
to Protein Conformation to State Switching in Ion Channels	42	Recommended Reading	109
III IOII CHAIIIICIS	77	References	103

6 Modelling Tissues and Organs	9.3 The Computational	Ecosystem 189
	9.4 Computing Reyord	
6.1 Introduction	9.5 Executing Simulation	
6.2 Modelling Epithelia	Performance Env	
6.3 Cardiac Modelling Box 6.1 The Navier–Stokes Equations	9.6 Case Study: Calculat	ing Drug
for Fluid Flow	122 Binding Affinities	193
6.4 GI Tract Modelling	9.7 Computational Infra	astructures 194
6.5 Modelling Kidney Function and	9.8 Distributed Applica	tions 197
Homeostasis	9.9 Orchestrating Work	
6.6 General Homeostasis and Blood-Press	re Distributed Appli	
Regulation	9.10 Case Study: Compo	
6.7 Conclusions	of Cranial Haemo 9.11 Conclusions	
Recommended Reading	136	205
References	Recommended Reading	
	References	206
7 Multi-Scale Modelling and Simulation	138	
7.1 Introduction: Multi-Scale Modelling in	10 Security and Privacy	in Sharing Patient Data 207
Computational Physiology	138 10.1 Introduction	207
7.2 Why Multi-Scale Modelling?	141 10.2 The Legal Background	und 209
7.3 A Framework for Multi-Scale Modellin	Box 10.1 Regulation	ons and Directives 209
and Computing	142 10.3 A Brief Overview o	f Information Security
7.4 Scale Bridging	148 Concepts	214
7.5 Multi-Scale Computing	150	ion Security Overview 214
7.6 Case Study of a Multi-Scale Model:	10.4 The Data-Sharing	
In-Stent Restenosis in Coronary Art		
7.7 Conclusions	158 10.6 Conclusions	228
Recommended Reading	Recommended Reading	
References	159 References	230
8 Workflows: Principles, Tools, and Clinic	l 11 Toward Clinical Depl	oyment: Verification
Applications	and Validation of Mo	odels 232
8.1 Introduction	161 11.1 Introduction: Heal	th Technology
8.2 Computational Workflows	162 Assessment	232
8.3 Implementing Workflows	169 Box 11.1 EU Defir	
8.4 Provenance	Device	234
8.5 Examples of Scientific Workflows	11.2 Code and Model V	
8.6 Some Key Considerations in Workflow	11.3 Sensitivity Analysi	
Design	11.4 Model Validation	236
8.7 Conclusions	11.5 Validation of Integ	
List of Projects Referenced	11.6 Clinical Accuracy	239
Recommended Reading	184 11.7 Efficacy, Risk, and Analysis	Cost-Benefit 243
References	184 11.8 Impact	244
	11.9 Sustainability	24-
9 Distributed Biomedical Computing	186 11.10 Conclusions	250
9.1 Introduction	186 Recommended Reading	
9.2 Parallel Applications	187 References	25

Appendix: Markup Languages, Standards, and Model Repositories		A.4 Markup Languages	256
	252	A.5 Model Repositories	261
A.1 Introduction	252	A.6 Conclusions	263
A.2 Infrastructure for Computational		References	264
Biomedicine	253		
A.3 Syntax, Semantics, and Annotation of		Glossary	265
Models	254	Index	273

ONLINE RESOURCE CENTRE

The Online Resource Centre to accompany *Computational Biomedicine*, at http://www.oxfordtextbooks.co.uk/orc/coveney/, features the following materials to support teaching and learning:

- Figures from the book in electronic format, for use in lecture slides [for registered adopters of the book only];
- Additional materials to augment topics discussed in certain chapters.

1 Introduction

Learning Objectives

After reading this chapter, you should:

- understand the concept of and the philosophy behind human systems biology and its application in translational medicine;
- be able to describe the philosophy behind major international and multidisciplinary initiatives in this field such as the European Commission's Virtual Physiological Human programme;
- have an overview of topics that will be introduced throughout this book.

1.1 Introduction

When our children and grandchildren visit their doctors in the latter part of this century, what will they find? They may encounter computer-based avatars of themselves, programmed with their individual genetic makeup and physiological conditions. Doctors will be able to use these to refine and test tailor-made, personalized treatment programmes. 'One size fits all' medicine would then truly be part of the past.

If this vision of the future of medicine is to come to pass it will owe much to the new discipline of computational biomedicine. This represents an important paradigm shift in the biomedical sciences and clinical medicine in the early twenty-first century, and it is the topic of this book. Computational biomedicine itself owes much to the last revolution in biomedicine: human genomics [1]. The human genome sequence was first published in 2003 as the culmination of an international project that had taken about 18 years and cost an estimated US\$2.7 billion (see http://www.genome.gov). Yet the pace of technological development has advanced so rapidly in

the 10 years or so since then that the cost of sequencing a single human genome is already well below \$10 000 and may well drop to the tantalizing figure of \$100 or even less within a few years. By then, the much heralded era of personalized genomics-but not yet that of fully personalized medicine-will have arrived. Already, direct-to-consumer businesses are being set up to profile genomes and feed information back to individuals, providing advice and counselling where needed. The first of these to be set up, such as California-based 23andMe1, work with profiles based on 0.5-2 million 'interesting' base positions out of the 3.2 billion in the human genome, but similar services based on profiles of the complete genome are not far behind. Furthermore, 23andMe engages its users in research into the genetic causes of disease by encouraging them to take part in surveys and linking user-reported disease incidence to known genotypes.

The growing influence of molecular biology on medicine during the 60-odd years since the discovery

¹ https://www.23andme.com/

of the structure of DNA cannot be doubted. However, it is becoming increasingly clear even to professional geneticists that knowing an individual's genome sequence cannot answer all the questions about their risk of and predisposition to disease and that genomics by itself will never be able to answer all research questions in biomedicine. After all, we humans have (approximately) a mere 23 000 genes in our genomes, fewer than many more primitive organisms. This apparent paradox can be at least partly resolved by considering the complexities that arise from non-linear interactions between genes and their protein products. As yet, we understand only a small part of the function and mechanism of gene-gene, gene-protein, and protein-protein networks and interactions.

Yet even this is not sufficient to explain the full complexity of human physiology. These complex regulatory networks are themselves influenced by events that occur at longer length and timescales than molecular ones, at the level of cells, tissues, organs, individual organisms, and their environment [2,3]. The ways in which interactions and events that occur on the level of an organism's phenotype can act as determinants of genetic behaviour—so-called downward causation as opposed to the upward causation that is the equally important influence of genetic interactions on physiology—are described by Denis Noble in *The Music of Life* [4].

1.2 Systems Biology

The study of living organisms as systems built from different spatial and temporal levels, and the interactions between them, is termed systems biology. Due to its intrinsic complexity, this type of study necessarily involves computer-based modelling and simulation. The techniques that are used can be generically termed computational biomedicine, and this is the title that has been given to our book.

Any given biological phenomenon, whether associated with normal human (or animal) physiology or with disease, is modelled, in Nobel laureate Sydney Brenner's famous phrase, 'from the middle out' [5]. This involves constructing a computational description of the phenomenon based on the most appropriate level of complexity while building in

connections from levels both above and below it in the hierarchy [6]. For example, a model of a single cardiac cell might start with equations for currents passing across its membrane through ion channels, whereas a model of the whole heart would start with equations that model its electrical activation and muscle contraction on a much larger scale. This approach is interdisciplinary and relies on scientists trained in disciplines as disparate as mathematics and computation, physics, chemistry, molecular and cell biology, physiology, and medicine collaborating together. It also involves engineers, at least where the modelling of tissues and organs is involved, and, wherever possible, clinicians.

Systems biology is often thought of as being intimately linked to another computational discipline: bioinformatics. This term is used to describe the computational analysis of biological data: generally, but not always, molecular-scale data such as gene sequences and protein structures. Yet these two complementary disciplines are essentially based on completely different philosophical approaches. Systems biology can be thought of as a scientific implementation of the ideas of philosopher Sir Karl Popper (1902-1994), in which models based on aspects of reality are used to make predictions that are tested through observation. The models are judged on their ability to correctly predict natural phenomena. These models will always be approximate and provisional, as adjustments will always be necessary following observations of the external system being modelled: much more rarely, a model will be completely redesigned after the paradigm on which it is constructed is rethought. This cycling from model to observation and back again (or hypothesis testing) is in tune with the way that many biologists think.

Bioinformatics, in contrast, is based on an 'inductivist' view of science derived from the thinking of philosopher Sir Francis Bacon (1561–1626), a pioneer of the scientific method. Put simply, this states that data (and look-up tables) are all that are needed for a complete scientific understanding of phenomena. There is no need for models; should discrepancies between predicted and actual phenomena be observed, it will always be possible to resolve these once sufficient data have been collected. These two approaches remain complementary, however. We still know remarkably little about the fundamental